Martin “Marty” Makary, a key supporter of the Trump administration’s health agenda, has resigned as the FDA commissioner. His departure follows reports that President Trump planned to dismiss him. Makary, a former surgical oncologist at Johns Hopkins, faced significant challenges during his tenure, including controversies over abortion and agency layoffs. He was known for criticizing public health responses to COVID-19 and was appointed by Trump in 2024. Makary’s tenure was marked by disagreements with administration figures, particularly over the approval of flavored vape products and the abortion pill mifepristone. He also made controversial decisions, such as removing a warning on estrogen and banning artificial food dyes. His resignation raises questions about the FDA’s future direction and its drug approval process.
QUESTION: How might changes in leadership at the FDA impact public health policies and the approval of new treatments?
Trump’s FDA Commissioner Marty Makary resigns
